In our twice-weekly chats, I often suggest investments that are part of large tech sectors.
For instance, the life sciences field defines huge. Just the prescription drug segment alone will be worth $1.2 trillion by 2024, according to data from Statista.
So, you might be wondering why I am focused on a medical area that will be worth just 0.1% of that figure over roughly the same time frame.
It’s a fair question. The answer is pretty basic. A high-octane leader
focused on specialty drugs can make a killing.
And the one I’m going to reveal to you today defines profit machine. It’s on pace to double per-share earnings in as little as a year.
I want to start today’s chat with a tech-investing challenge.
How many of you can claim you have a stock in your portfolio that is up nearly 230% in just 16 months?
As impressive as that return sounds, it actually understates the strength of the stock I have in mind. It’s a medical device leader that recently received approval for a Covid-19 test.
It’s up 120 in the past two months alone…
But this is no flash in the pan. Even before that breakthrough occurred, the stock was a bona fide market crusher
From roughly the beginning of 2019 through the correction that began on February 19, the stock was ahead of the S&P 500 by an amazing 278.5%.
The firm I have in mind is leading the medical device market as part of a trend toward remote patient monitory.
With the coronavirus still fresh on everyone’s minds, the investment thesis is only getting better.
Not even a brutal market selloff can keep Amazon.com Inc. (AMZN) down.
Here’s the thing. This is no ordinary bear market, one defined as a 20% drop from the previous high.
It’s the coronavirus panic that has most of the economy in a deep freeze.
As a result, physical retail stores are getting hammered. The U.S. Commerce Department says retail sales for March fell a seasonally adjusted 8.7%.
That’s the biggest one-month decline since the agency began keeping records back in 1992.
And while Amazon definitely faced some supply chain issues, the King of E-commerce came through when the nation needed the tech giant’s help the most. It delivered millions of packages to homebound families all across America.
With that performance under its belt, yesterday the firm’s stock hit a record high – a feat that few stocks can match.
The coronavirus crisis is an event like nothing we’ve seen before in our lifetimes. It’s put an unprecedented strain on our economy by forcing people to stay in their homes. The markets may be down, but many of the same high-tech innovations that drove the pre-virus economy to new heights are helping society stay connected now. That means working from home, shopping for necessities online, and keeping in touch with friends and family. In short, online infrastructure has gone from convenient to totally indispensable. This is a prime opportunity for any online innovator to rise to the occasion, and rise in value. And when this crisis passes, tech will be poised to lead the market again. Click here to watch.
When we spoke on Tuesday, I made a bold prediction: the Covid-19 outbreak, while serious, will not be as bad as the worst-case predictions would have it.
For one, much of the country is already on lock-down, cutting off the spread of the disease. That is buying us some valuable time as researchers race to find a cure or at least a good treatment option.
And I’m happy to report there have been some exciting developments in the search for treatments and vaccines against Covid-19
Last week, I noted that most vaccine research remains rooted in 1950s technology.
Despite mapping the entire human genome back in April 2004, drug firms and scientists still rely on slowly growing viruses inside chicken eggs to create a vaccine.
This takes a lot of time – and a lot of eggs.
But the Covid-19 pandemic has them racing to find a treatment using novel and fascinating science.
Millions of Americans found yesterday’s headlines about the coronavirus more than a little disturbing.
After all, the number of U.S. cases has climbed above 10,000. And while that sounds like a lot from the standpoint of raw numbers, I believe at a time like this, it’s important to keep this kind of news in context.
In fact, I’m going to go out on a limb here and predict that the total number of infected Americans will be much less than what Big Media would have you believe.
I realize that many folks are scared and frustrated because the $1.2 trillion life sciences sector has not yet released a vaccine.
With that in mind, I am starting the first of a two-part series on that very subject.
Today, I will walk you through why we still use 1950s technology in the search for a vaccine.
As you are no doubt aware, the markets have come under extreme pressure of late.
It’s all about the fears we see regarding a new virus, Covid-19, better known as the coronavirus. Overall we are coming through the selloff in pretty good shape.
But there’s no doubt we have given up a lot of gains as have millions of others. In fact, I have been getting a number of questions from concerned investors.
When he passed away last September at the age of 91, T. Boone Pickens generated dozens of media biographies.
Of course, a billionaire with his reputation as a savvy business leader would no doubt get lots of obituaries written about him.
Here’s the thing; of the several accounts I read, most focused on his very successful career as an oil and gas baron.
It’s easy to see why. After all, in 2007 alone, he is reported to have earned more than $2.7 billion from his two energy-investing funds.
So, it may sound ironic for me to suggest that those obituaries were inaccurate.
I say that because at least two years before his death, Pickens went through a sea change and closed his energy funds. The reason: he became a massive backer of solar technology.
Please don’t think I’m pulling out an isolated case to show that solar has passed the tipping point.
Today, I’m going to show you why deep in the heart of America’s coal country, experts are putting their faith in sunlight.
When it comes to investing in e-commerce, most people think about Amazon.com Inc. (AMZN) and pretty much leave it at that.
Don’t get me wrong, I’m in no way backing off my bullish belief in Amazon.
After all, we recently had two conversations about the potential double ahead for the King of E-commerce.
The point of today’s chat is to show you how much money you can make by finding a great backend play on a booming sector.
Even better if the firm in mind is a high-growth outfit that flies under Wall Street’s radar. That way you can get in before the so-called “smart money” shows up, and pile up even more profits.
And that’s the exact setup we find with a company I refer to as “Amazon’s Hidden Supercharger.”
Since February 2, 2016, when it hit a post-IPO low up, until February 4 of this year, this stock has gone up 2,409%.
That’s the equivalent of turning $25,000 into $627,500.
My wife and I recently helped our daughter Jordan find a reliable used car.
And since Jordan only recently got her grad degree, I have to say she was pretty price sensitive.
She had roughly $9,000 to put down and wanted to limit her payments to about $100 a month, so there wasn’t a lot of wiggle room on cost. She bought, a 2009, one-owner, fully loaded Honda CRV with only 45,000 miles on it.
I’m bringing this up to you because I think our recent experience illustrates a very important point for tech investors.
When it comes to putting your money in stocks that can crush the market, don’t let high “sticker prices” warn you off of great opportunities to build lasting wealth.
Instead, you have to focus on the long-term upside. You know, it’s the old saw by Warren Buffett that price is what you pay but “value is what you get.”
And that really comes into play with a firm that is pioneering the field of robotic surgery.
At first glance, $600 a share seems steep. But this is a stock that could hit $1,800 a shares in as little as seven years.
